Biotage AB (BIOT) AI Stock Analysis

• Market Cap: kr11.45B
• Dividend Yield: 1.15%
• Average Volume (3M): 172.60K
• Price to Earnings (P/E): 44.7
• Beta (1Y): 0.92
• Revenue Growth: -1.01%
• EPS Growth: 6.10%
• Country: SE
• Employees: 622
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.62
• Shares Outstanding: 80,051,880
• 10 Day Avg. Volume: 39,410
• 30 Day Avg. Volume: 172,598
• PEG Ratio: -4.40
• Price to Book (P/B): 2.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 59.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr143.02
• Price Target Upside: 0.09% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 72 Outperform
• Price Target: ―

Biotage AB demonstrates strong financial performance with solid profitability and balance sheet stability. However, the technical analysis suggests caution due to potential overbought conditions and mixed price trends. The valuation appears high, which might limit upside potential despite a reasonable dividend yield. Overall, the company is fundamentally strong, but market conditions and valuation demand careful consideration.

Biotage AB Business Overview & Revenue Model

Company Description

Biotage AB is a global life sciences company that provides innovative solutions in the fields of chemistry and biology. The company specializes in developing technologies and products for medicinal chemistry, analytical chemistry, and process development. Biotage's offerings include systems and consumables for sample preparation, purification, evaporation, and synthesis, serving industries such as pharmaceuticals, biotechnology, and environmental analysis.

How the Company Makes Money

Biotage AB generates revenue primarily through the sale of its products and technologies to various industries, including pharmaceuticals, biotechnology, and academic research. The company's key revenue streams come from its comprehensive range of systems, consumables, and services that facilitate efficient sample preparation, purification, and synthesis. Additionally, Biotage may engage in strategic partnerships and collaborations that contribute to its earnings by expanding its market reach and enhancing product offerings. The company's ability to innovate and provide quality solutions tailored to the needs of its clients is a significant factor in its revenue generation.

Biotage AB Financial Statement Overview

Summary

Biotage AB presents a strong financial profile with robust revenue growth, profitability, and balance sheet stability. The company effectively manages its debt, maintaining low leverage while generating consistent earnings and cash flow. Despite some fluctuations in growth rates and margins, Biotage AB remains well-positioned within the Medical - Instruments & Supplies industry.

Income Statement

Biotage AB has demonstrated strong financial performance with consistent growth in revenues and net income over the years. The company maintains a healthy gross profit margin of 62.7% for TTM, indicating efficient cost management. However, the net profit margin for TTM has slightly decreased to 13.1% from the previous annual figure of 13.8%. The revenue growth rate shows a slight decline of 4.6% from 2024 to TTM, but overall, the company's income statement reflects robust profitability and growth.

Balance Sheet

The balance sheet of Biotage AB is solid with a strong equity base, reflected in an equity ratio of 81.7% for TTM. The company has effectively managed its debt levels, with a low debt-to-equity ratio of 0.06. Return on equity stands at 6.7% for TTM, indicating moderate efficiency in generating returns for shareholders. Overall, the balance sheet showcases financial stability with low leverage and high shareholder equity.

Cash Flow

Biotage AB's cash flow statement indicates healthy cash generation capabilities, with a free cash flow of 188 million for TTM. However, the free cash flow has decreased by 22.9% compared to the previous year. The operating cash flow to net income ratio of 1.36 for TTM suggests efficient cash conversion from net income. Despite a decline in free cash flow, the company maintains a strong operating cash flow, reflecting good liquidity and cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.06B	1.86B	1.57B	1.23B	1.09B
Gross Profit	1.29B	1.01B	948.00M	755.00M	666.73M
EBITDA	530.00M	432.00M	431.00M	323.00M	278.10M
Net Income	284.00M	246.00M	268.00M	205.00M	175.00M
Balance Sheet
Total Assets	5.10B	4.93B	2.34B	1.99B	1.43B
Cash, Cash Equivalents and Short-Term Investments	434.00M	594.00M	441.00M	311.00M	371.32M
Total Debt	250.00M	259.00M	217.00M	203.00M	212.69M
Total Liabilities	991.00M	1.27B	702.00M	620.00M	444.40M
Stockholders Equity	4.11B	3.66B	1.64B	1.37B	990.04M
Cash Flow
Free Cash Flow	244.00M	258.00M	271.00M	297.00M	218.11M
Operating Cash Flow	413.00M	284.00M	341.00M	353.00M	279.05M
Investing Cash Flow	-456.00M	35.00M	-84.00M	-341.00M	-61.32M
Financing Cash Flow	-156.00M	-142.00M	-133.00M	-82.00M	-22.72M

Biotage AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 142.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOT, the sentiment is Positive. The current price of 142.9 is above the 20-day moving average (MA) of 142.89, above the 50-day MA of 142.34, and above the 200-day MA of 139.81, indicating a bullish trend. The MACD of 0.60 indicates Positive momentum. The RSI at 58.66 is Neutral, neither overbought nor oversold. The STOCH value of 27.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOT.

Biotage AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUS	73 Outperform	kr7.85B	54.50		―	12.41%	-32.19%
BIOT	72 Outperform	kr11.45B	44.71	6.41%	1.15%	-1.01%	6.10%
RAY.B	70 Neutral	$12.36B	55.27	25.53%	0.82%	20.72%	122.06%
BONEX	70 Neutral	$21.00B	144.05	20.14%	―	44.52%	-49.29%
ALIF.B	66 Neutral	$21.34B	63.57	6.27%	0.43%	4.56%	185.59%
XVIVO	60 Neutral	$6.89B	59.96	5.17%	―	17.78%	-7.83%
Sector *	52 Neutral	$7.34B	-0.07	-63.86%	2.34%	16.17%	0.23%

Biotage AB Corporate Events

Biotage AB Announces Extraordinary General Meeting Amid Ownership Changes

Biotage AB has announced an Extraordinary General Meeting (EGM) scheduled for August 7, 2025, following a request from RWK Bidco AB, which now owns over 90% of Biotage’s shares. The meeting will address changes in the Articles of Association, board member elections, and adjustments related to the delisting of Biotage’s shares from Nasdaq Stockholm, indicating significant corporate restructuring and potential impacts on governance and shareholder engagement.

Biotage AB Announces Delisting from Nasdaq Stockholm

Biotage AB has announced its decision to apply for delisting from Nasdaq Stockholm following RWK BidCo AB’s acquisition of over 90% of its shares and initiation of compulsory redemption proceedings for the remaining shares. This strategic move will be followed by an Extraordinary General Meeting on August 7, 2025, to elect new board members, signaling a significant shift in the company’s governance and market presence.

Biotage AB Increases Voting Rights Through Share Reclassification

Biotage AB has re-classified 2,611 class C shares to ordinary shares as part of its long-term incentive plan from 2022. This re-classification has increased the total number of votes in the company by 2,349.9, while the total number of shares remains unchanged, reflecting a strategic move to fulfill commitments to participants in the incentive plan.